Cresset

Cresset is a United Kingdom-based company, headquartered in Cambridge, that develops digital molecular discovery software and provides related discovery services for the pharmaceutical and biotechnology industries. Its stated mission is to help discovery teams "generate smarter ideas, make stronger decisions, and design better molecules," bringing computational and medicinal chemists together to streamline discovery from target validation through to candidate selection. The company describes itself as leading a digital revolution in molecule design and cross-team communication, combining cutting-edge science with AI and machine learning so that customers can discover new compounds faster and more efficiently. Cresset's offering is built around a suite of computational chemistry software products. Flare™ is its ligand- and structure-based design platform; Spark™ provides scaffold hopping and bioisosteric replacement; Flare™ FEP predicts binding affinity and supports lead optimisation; Blaze™ performs ligand-based virtual screening for hit discovery; and AI-powered ADME model building generates predictive absorption, distribution, metabolism and excretion models from customer data. Additional tools include Flare™ Connect for collaborative, chemistry-aware teamwork, Lead Finder™ for high-throughput docking, PickR™ for selecting electrostatically diverse monomers, XedTools™ command-line utilities that expose Cresset's XED force field, and the Cresset Engine Broker™ for running calculations on remote servers or clusters. Alongside software, Cresset offers Discovery Services as a partner for digital molecular discovery. The company positions itself as a trusted partner for digital molecular discovery, serving customers ranging from biotechs to large pharma, and states that it is a secure and responsible business. Its solutions are sold directly in some territories and through a distribution network in others. Cresset says its platform is built from 20 years of computational chemistry innovation, and it enriches its validated simulation science with focused use of AI. The company also maintains an active news and events programme, publishing product releases, case studies, webinars and conference appearances, and it has expanded through acquisitions such as Molab.ai in 2025. Cresset's scientific credibility is reinforced by customer and academic use of its technology, including published research in journals such as the Journal of Medicinal Chemistry and In Silico Research in Biomedicine. The company presents itself as a partner that helps create a healthier world through state-of-the-art drug-discovery solutions, and it emphasises collaboration and insights across the Design-Make-Test-Analyze cycle.

Cresset is a Cambridge, United Kingdom-based company operating in the digital molecular discovery space. According to its own account, its platform is built from 20 years of computational chemistry innovation, and the company has evolved into a provider of AI-enriched simulation science solutions for drug discovery teams. Its stated purpose is to lead the digital revolution in molecule design and cross-team communication, combining cutting-edge science with AI and machine learning to help customers discover new compounds faster and more efficiently. Over time Cresset has assembled a portfolio of software products spanning ligand- and structure-based design, scaffold hopping, binding affinity prediction, virtual screening, ADME modelling and collaborative chemistry-aware workflows. Its flagship products include Flare™, Spark™, Flare™ FEP and Blaze™, supported by tools such as Lead Finder™, PickR™, XedTools™ and the Cresset Engine Broker™. The company also offers Discovery Services, positioning itself as a partner for digital molecular discovery rather than only a software vendor. Cresset serves customers from biotechs to large pharma and describes itself as a secure and responsible business. Its solutions are available through direct sales in some territories and through a distribution network in others. The company maintains an active programme of product releases, case studies, webinars and conference appearances. Notable recent developments include the release of Flare™ V11 in December 2025, which the company said unlocked AI-driven efficiency gains, and the acquisition of Molab.ai in July 2025 to advance the digitization of drug discovery. In March 2026 the company announced a new Cresset designed in partnership with its customers, and in June 2026 it released Flare V12, aimed at cutting synthesis and testing cycles with faster, more flexible FEP. Cresset Discovery has also reported accelerating the optimization of a METTL3 inhibitor. The company's scientific standing is reflected in the use of its technology in published research, including a DNA-encoded library screen identifying novel series of respiratory syncytial virus polymerase inhibitors in the Journal of Medicinal Chemistry, and machine learning-based 3D-QSAR models for predicting estrogen receptor-binding activity of small molecules in In Silico Research in Biomedicine.

• Cresset acquires Molab.ai to advance digitization of drug discovery.

• Cresset Discovery accelerates optimization of a METTL3 inhibitor.

• Release of Flare™ V11, described as unlocking AI-driven efficiency gains.

• Announcement of a new Cresset designed in partnership with customers.

• Release of Flare V12 to cut synthesis and testing cycles with faster, more flexible FEP.

Trusted partner for digital molecular discovery, combining validated simulation science with focused AI to serve biotechs and large pharma.

• Flare™

  Ligand- and structure-based design software for small molecule discovery.

• Spark™

  Scaffold hopping and bioisosteric replacement technology.

• Flare™ FEP

  Free energy perturbation for predicting binding affinity and supporting lead optimisation.

• Blaze™

  Ligand-based virtual screening to boost hit discovery and reduce wet-lab screening costs.

• AI-Powered ADME model building

  Build reliable, predictive ADME models powered by AI, generated from customer data.

• Flare™ Connect

  Chemistry-aware collaborative platform for teamwork and partnership.

• Lead Finder™

  High-throughput docking for generating leads.

• PickR™

  Select electrostatically diverse monomers for high quality libraries and better intellectual property.

• XedTools™

  Command line utilities giving access to Cresset's XED force field.

• Cresset Engine Broker™

  Run calculations on a remote server or cluster to speed up drug discovery experiments.

• Discovery Services

  Partnered digital molecular discovery services.

1. 1Better molecules, by design - Cressetcresset-group.com
2. 2About Cresset - Cressetcresset-group.com
3. 3Digital molecular discovery solutions - Cressetcresset-group.com
4. 4News - Cressetcresset-group.com
5. 5Cresset (United Kingdom) - Wikidatawikidata.org